First surgical procedures performed in the USA with the Jazz PF tethering implant

834
Jazz PF implant

Implanet has announced that the first surgeries have been conducted in the USA with its Jazz PF tethering implant.

Jazz PF is designed to allow surgeons to create a soft landing of posterior spinal constructs in order to prevent proximal junctional kyphosis (PJK)—a relatively common and serious complication following adult spinal deformity surgery, say the company. The implant creates a stiffness gradient, between the upper instrumented vertebrae and the tethered proximal segmental level.

The Jazz PF solution has obtained CE marking in Europe as well as 510(k) regulatory clearance from the US Food and Drug Administration.

William Barrick, of Orthopedic Associates (Poughkeepsie, USA), said: “I have been using Implanet’s Jazz Band for some time, with excellent results in complex adult spinal deformity indications. The addition of Jazz PF to Implanet’s range is a major breakthrough in the protection of the adjacent level.

“This new implant has been easy to use during the first surgical procedures and has supplied encouraging early post-operative clinical results. We will monitor these patients to confirm these results over the longer term. I believe that Jazz PF will rapidly become an essential tool for spine surgeons.”

Ludovic Lastennet, CEO of Implanet, added: “Jazz PF provides a response both to the issues surgeons face in degenerative disorders and more importantly to the budgetary requirements placed on American healthcare facilities during this post-pandemic period.

“This new implant was launched in Europe last September, and the marketing of this unique solution on the US market by our Implanet America team began during the final quarter of 2021.

“This concept has rapidly generated considerable interest from spine surgeons specialising in the treatment of large deformities in adults, the first step in positioning ourselves in this large-scale market estimated at 37,000 surgical procedures and to be worth US$348 million a year. For the first time, we have a universal solution that can be used in 25 to 30% of procedures.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here